Aurinia Pharmaceuticals Inc. Tax Withholding Paid on Stock Awards
Aurinia Pharmaceuticals Inc. (AUPH) reported Tax Withholding Paid on Stock Awards of $26.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $11.87M, a 11428.16% increase year-over-year.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $14.58M, a 63.22% increase year-over-year.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $364.00K, a 50.41% increase year-over-year.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $364.00K, a 117.96% increase year-over-year.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $9.76M, a 59.18% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $6.13M, a 169.15% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $2.28M, a 119.13% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $1.04M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $26.45M 10-Q · filed 2026-08-06 | $26.82M derived: sum of 3 quarters · filed 2026-08-06 | $27.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.58M 10-Q · filed 2026-05-07 | $14.94M derived: sum of 2 quarters · filed 2026-05-07 | $15.31M derived: sum of 3 quarters · filed 2026-05-07 | $15.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $728.00K derived: sum of 2 quarters · filed 2026-02-26 | $831.00K derived: sum of 3 quarters · filed 2026-08-06 | $9.76M 10-K · filed 2026-02-26 |
| 2025-09-30 | $364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $467.00K derived: sum of 2 quarters · filed 2026-08-06 | $9.40M 10-Q · filed 2025-11-04 | $9.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.04M 10-Q · filed 2026-08-06 | $9.28M derived: sum of 3 quarters · filed 2026-08-06 | $9.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.93M 10-Q · filed 2026-05-07 | $9.18M derived: sum of 2 quarters · filed 2026-05-07 | $9.34M derived: sum of 3 quarters · filed 2026-05-07 | $9.57M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $409.00K derived: sum of 2 quarters · filed 2026-02-26 | $638.00K derived: sum of 3 quarters · filed 2026-02-26 | $6.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $396.00K derived: sum of 2 quarters · filed 2025-11-04 | $5.89M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $5.72M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $5.50M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $2.28M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $1.04M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |